HSA/FSA for GLP-1: What Qualifies (2026)

HSA vs FSA — which account covers GLP-1s?

Both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) are governed by the same underlying IRS eligibility rules for medical expenses — so the question of whether a GLP-1 qualifies is the same for both accounts. The practical differences are in how each account is funded and what happens to unspent money:

Source: IRS Publication 969 — Health Savings Accounts and Other Tax-Favored Health Plans.

Because HSA funds never expire, they can be a strategic account for a multi-month GLP-1 program: you pay today, save the receipt, and submit for reimbursement at any point — even years later — as long as the expense occurred after the account was established.

When a GLP-1 qualifies for HSA/FSA reimbursement

Under IRS Publication 502, weight-loss treatment qualifies as a medical expense when a physician prescribes it to treat a specific disease. The IRS has confirmed that obesity itself qualifies as a disease for this purpose, as do related conditions commonly treated with GLP-1s:

• Obesity (BMI ≥ 30, or ≥ 27 with a weight-related comorbidity)
• Type 2 diabetes
• Cardiovascular disease or elevated cardiovascular risk
• Obstructive sleep apnea

A GLP-1 prescription for cosmetic weight loss — where no clinical diagnosis is driving the treatment — is not eligible. The determining factor is the clinical indication in your prescription, which is why documentation from your provider matters.

Which GLP-1 medications are HSA/FSA eligible?

Ozempic and Wegovy (semaglutide)

Ozempic® (semaglutide, indicated for type 2 diabetes) and Wegovy® (semaglutide, indicated for chronic weight management) are both prescription medications, and both may be eligible for HSA/FSA reimbursement when prescribed for a qualifying diagnosis. Wegovy® carries an FDA-approved indication for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity — this aligns directly with the IRS disease-treatment standard. Ozempic's primary indication is type 2 diabetes, which also qualifies. A Letter of Medical Necessity is commonly requested by administrators for either medication when the listed diagnosis relates to weight management. See NIDDK's overview of prescription weight-management medications for clinical context.

Mounjaro and Zepbound (tirzepatide)

Mounjaro® (tirzepatide, indicated for type 2 diabetes) and Zepbound® (tirzepatide, indicated for chronic weight management and obstructive sleep apnea) follow the same eligibility framework. Zepbound® has an FDA-approved indication for both obesity and OSA, both of which are recognized diseases under IRS rules. As with semaglutide-based medications, a Letter of Medical Necessity helps document that the prescription is treating a qualifying diagnosis rather than serving a cosmetic purpose.

Can you use HSA/FSA for compounded GLP-1?

This is where eligibility becomes more nuanced. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name medications. They are prepared by state-licensed 503A compounding pharmacies and prescribed on a patient-specific basis when a licensed provider determines it is clinically appropriate. See the FDA's guidance on human drug compounding for background on the regulatory framework.

Under IRS Publication 502, the eligibility test focuses on whether the expense is for a prescription drug used to treat a diagnosed medical condition. Compounded medications prescribed under those conditions can satisfy this standard — but because compounded drugs are not FDA-approved, plan administrators are more likely to:

• Request an LMN and a copy of the prescription
• Ask for pharmacy documentation showing the compounded preparation was lawfully dispensed
• Apply additional scrutiny or deny claims if documentation is incomplete

Keep a thorough paper trail: the prescription, the pharmacy receipt with the compounded medication's name, your LMN, and the diagnosis code your provider is treating. The plan administrator has final authority on reimbursement.

For context on compounding safety and regulatory status, the FDA maintains postmarket safety information on compounded GLP-1 products.

The Letter of Medical Necessity — what it is and how to get one

An LMN is a document from your licensed provider that explains, in writing, why a specific treatment is medically necessary for you. For a GLP-1 prescription, a strong LMN typically includes:

• Your diagnosis (e.g., obesity, type 2 diabetes) and relevant clinical details (BMI, comorbidities)
• The specific medication prescribed and the dosage plan
• A statement that the treatment is medically appropriate for your condition — not for cosmetic purposes
• The provider's name, credentials, contact information, and signature
• The date of the evaluation

How to get one: ask your prescribing provider at the time of your intake evaluation. Telehealth providers can issue an LMN based on a virtual evaluation; it carries the same weight as one from an in-person visit. Most plan administrators accept an LMN submitted with your receipt when you file the reimbursement claim. Keep a copy for your records — some administrators request it at the time of the claim, others only when a claim is disputed.

How to file an HSA or FSA reimbursement claim

The process is straightforward and the same whether you have an HSA or FSA:

1. Pay out of pocket at the pharmacy (or when your telehealth program charges you).
2. Save your itemized receipt showing the medication name, date, and amount paid.
3. Log into your HSA/FSA administrator's portal (often a benefits platform like Optum Bank, HealthEquity, WEX, or your employer's portal).
4. Submit the claim with your receipt and, for a GLP-1, attach your LMN. Some administrators accept digital uploads; others require a form.
5. Receive reimbursement directly to your bank account or as a check, typically within a few business days to a few weeks.

A few practical notes:

• FSA funds have a deadline — typically December 31 of the plan year, with some plans allowing a grace period or small carryover. Don't let a year-end deadline pass on a large GLP-1 expense you could have claimed.
• Some HSA/FSA debit cards attempt to adjudicate purchases at the point of sale. GLP-1 prescriptions may not auto-approve at the terminal, even when eligible — the reimbursement-submission route is more reliable.
• If a claim is denied, appeal it with your LMN and the relevant IRS Publication 502 language. Many first-time denials are documentation issues, not outright ineligibility.

What is NOT eligible under HSA/FSA for GLP-1s

Knowing the disqualifying scenarios saves a denied claim:

• Cosmetic weight loss — prescriptions written for appearance goals without a clinical diagnosis of a qualifying disease.
• Supplements and over-the-counter appetite suppressants — these are not prescription drugs and do not qualify under the prescription-drug rule.
• Gym memberships and fitness programs — general fitness expenses are not covered, even when part of a broader weight-management program (the medical prescription component is separate).
• Nutrition counseling not tied to a medical diagnosis — general dietary advice without a qualifying disease diagnosis typically does not qualify.

Telehealth prescriptions count

A prescription from a licensed provider issued via telehealth carries the same weight as an in-person prescription for HSA/FSA purposes — provided the evaluation was a genuine medical assessment by a licensed provider, not a rubber-stamp questionnaire. Plan administrators do not require in-person visits to accept an LMN or a prescription as documentation.

What Nouri includes — and how HSA/FSA reimbursement may apply

Nouri is a telehealth program that, when a licensed provider determines it is clinically appropriate, includes compounded semaglutide or compounded tirzepatide alongside a personalized nutrition plan, movement plan, and ongoing clinician support — all at one all-in price. All 50 U.S. states; adults only. Medication is prescribed only after a licensed clinician reviews your intake and determines it appropriate. Not all applicants qualify.

Nouri's pricing as of June 2026:

Current pricing at joinnouri.com/becoming. Any dose, same price; no per-dose surcharges. Source: Nouri GLP-1 telehealth pricing dataset, June 2026.

If your licensed Nouri provider determines that treatment is clinically appropriate and writes a prescription, that prescription — like any other lawfully written compounded GLP-1 prescription — may be eligible for HSA/FSA reimbursement under the same IRS rules described above. You would pay Nouri at checkout, save your receipt, and submit it to your HSA/FSA administrator along with your LMN. Ask your Nouri Care Team about an LMN at the time of your evaluation.

This is a reimbursement path, not a direct charge to your HSA/FSA card. Confirm eligibility and the documentation required with your specific plan administrator before proceeding.

Start your assessment with Nouri →
5-minute intake · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on the 3-month and 6-month plans · cancel anytime

Related cost guides

• GLP-1 Cost in 2026 — The Full Comparison
• How to Get a GLP-1 Covered by Insurance
• Does Insurance Cover Wegovy & Zepbound?
• Compounded vs Brand GLP-1 Cost
• Semaglutide Cost (With and Without Insurance)
• Tirzepatide Cost Without Insurance
• Cheapest Way to Get a GLP-1 — Full Comparison

Frequently asked questions

Can I use my HSA or FSA for Ozempic?

Yes, when Ozempic is prescribed to treat a diagnosed condition such as type 2 diabetes or obesity. A Letter of Medical Necessity is often recommended. Ozempic prescribed purely for cosmetic weight loss is not eligible. Confirm reimbursement eligibility with your plan administrator.

Is Wegovy FSA eligible for weight loss?

Wegovy may be FSA/HSA eligible when prescribed to treat obesity (a recognized disease under IRS Publication 502) or another qualifying condition. Plan administrators frequently ask for a Letter of Medical Necessity as documentation. Confirm eligibility and the reimbursement process with your specific plan administrator.

Do I need a letter of medical necessity to use HSA for a GLP-1?

It is strongly recommended and often required in practice. The letter, from your licensed provider, documents your diagnosis and that the medication is medically appropriate — which satisfies most plan administrators. Without it, a weight-loss prescription may be flagged as potentially cosmetic and denied on first review.

Can I use HSA/FSA for compounded semaglutide?

Compounded semaglutide may qualify under the same IRS rules if it is lawfully prescribed for a diagnosed condition, but because compounded drugs are not FDA-approved, expect more scrutiny from administrators. A Letter of Medical Necessity is especially important. Always confirm reimbursement eligibility with your plan administrator — they have final authority on claims.

Is Zepbound HSA eligible?

Zepbound may be eligible for HSA/FSA reimbursement when prescribed to treat a qualifying condition such as obesity or obstructive sleep apnea. A Letter of Medical Necessity is commonly recommended. Confirm eligibility with your plan administrator.

Is Mounjaro HSA/FSA eligible?

Mounjaro may be HSA/FSA eligible when prescribed to treat a diagnosed condition such as type 2 diabetes or obesity. A Letter of Medical Necessity is commonly recommended to satisfy plan administrators. Confirm reimbursement eligibility with your specific plan.

Will my FSA cover a GLP-1 prescribed for weight loss?

Generally yes, if it is prescribed to treat obesity (a recognized disease under IRS rules) rather than for cosmetic reasons. FSA administrators may request documentation, so have a Letter of Medical Necessity ready. Confirm the reimbursement process and documentation requirements with your plan administrator before submitting.

Sources & references

1. IRS Publication 502 — Medical and Dental Expenses (Internal Revenue Service)
2. IRS Publication 969 — Health Savings Accounts and Other Tax-Favored Health Plans (Internal Revenue Service)
3. Human Drug Compounding (U.S. Food and Drug Administration)
4. Prescription Medications to Treat Overweight and Obesity (NIDDK, National Institutes of Health)
5. Postmarket Drug Safety Information — GLP-1 / Compounding (U.S. Food and Drug Administration)
6. CMS Medicare GLP-1 $50 Monthly Access Program (Centers for Medicare & Medicaid Services)
7. Wegovy self-pay & savings (NovoCare) — verified June 2026
8. Zepbound self-pay vials (LillyDirect) — verified June 2026
9. GLP-1 Telehealth Pricing 2026 dataset (Nouri, June 2026)

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · June 29, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance and pricing change.

This article is general information, not medical, financial, or tax advice. HSA/FSA reimbursement eligibility depends on your specific plan and administrator; always confirm with your plan administrator and, for tax questions, consult a tax professional before making decisions. Prices described here are accurate as of June 2026 and change frequently — verify current figures with the manufacturer, pharmacy, or joinnouri.com/becoming before deciding. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Compounded medications are prescribed only when a licensed provider determines they are clinically appropriate for a specific patient.